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| INTRODUCTION
Thrombotic thrombocytopenic purpura (TTP) is a devastating disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ failure of variable severity. Historically, TTP had a fatal prognosis. This was transformed with the use of intensive therapeutic plasma exchange (TPE) in 1991. 1 In the following years, the rapid and systematic use of TPE in association with corticosteroids until durable remission emerged as the standard regimen for TTP treatment. In 1998, the identification of a dysfunction of the von Willebrand factor (vWF)-cleaving protease ADAMTS13 (A Disintegrin And Metalloproteinase with
ThromboSpondin-1 motifs; 13th member of the family) as a result of the production of autoantibodies against the enzyme in autoimmune TTP (iTTP) provided a rationale for the evaluation of B-cell depleting therapies. 2, 3 The addition of rituximab to the standard regimen in the mid-2000s represented the second breakthrough in the management of the disease. 4 Indeed rituximab, formerly administered as adjuvant therapy in iTTP in patients with a suboptimal response to the standard regimen, is now increasingly used frontline, and still more recently as a preemptive strategy to prevent relapse. 5 In the very near future, this therapeutic arsenal will be strengthened by more targeted therapies stemming directly from our understanding of disease pathophysiology, specifically recombinant ADAMTS13 and caplacizumab, an agent that inhibits platelets-vWF adhesion. In this review, we discuss recent advances as well as future perspectives in the rapidly evolving therapeutic landscape of TTP. and/or increase its clearance from the circulation by forming noncovalent circulating immune complexes. Models of passive transfer of autoimmunity in baboons and rodents have supported these concepts, 4 and led to wider use of immunosuppressive treatments.
| PATHOPHYSIOLOGICAL BASIS OF TTP TREATMENT
However, the immune cells precisely involved in the production of anti-ADAMTS13 autoantibodies and accounting for the remarkable efficacy of B-cell depleting agents in this disease remain to be identified.
| CLINICAL PRESENTATION
The epidemiology of iTTP and clinical features on presentation have now been well characterized from large national registries. 4, 5 The incidence of TTP has been reported to be two to four cases per million people per year. 6 iTTP occurs more frequently in females (3:2 female-to-male ratio) with a median age in the fourth decade.
While the onset of disease is typically sudden, prodromic manifestations including fatigue, arthralgias, myalgias, and abdominal and/ or lumbar pain suggestive of a flu-like illness are frequent. iTTP occurs in association with predisposing conditions in 50% of cases that need to be identified for appropriate management: connective tissue diseases, pregnancy, or more rarely HIV infection, and cancer. 6 Therefore, unexplained anemia and thrombocytopenia in such contexts should prompt investigation for possible underlying iTTP. 
| IMPORTANCE OF RAPID, ACCURATE DIAGNOSIS
With the increasing availability of effective treatments, rapid diagnosis of TTP by sensitive criteria is mandatory, and this urgency led to a decrease in the stringency of the diagnostic criteria in the clinical trial that documented the effectiveness of TPE. 
| THE CURRENT STANDARD OF CARE
TTP is a medical emergency and requires rapid diagnosis and urgent management. Older age, a very high LDH level (reflecting organ damage as well as hemolysis) and increased cardiac troponin level on diagnosis, are associated with death and treatment refractoriness.
Cardiac troponin assessment at the time of initial diagnosis to identify the more severe patients should be part of standard evaluation. 8, 9 TPE remains the cornerstone of current management of iTTP and should be started as soon as the diagnosis is strongly suspected.
Given the autoimmune nature of iTTP, there is a rationale for the use of corticosteroids, although evidence is limited [17] [18] [19] [20] (see Figure 1 ).
| IMMUNOMODULATION THROUGH B-CELL DEPLETION: WHERE DO WE STAND?
The introduction of the humanized anti-CD20 monoclonal antibody rituximab has been the second major breakthrough in iTTP management. Clinical studies conducted to assess the role of rituximab in iTTP have faced the usual challenges that confront clinical trials in rare diseases such as difficulty with recruitment and cross-over.
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These challenges are compounded in iTTP by the necessity to intervene rapidly, leaving little time for determination of eligibility and informed consent. As such, current knowledge about the use of rituximab in iTTP is based on observational studies that enrolled a limited number of patients and provide low to moderate levels of evidence. 
+1
Or reticulocyte count >2.5%
Or undetectable haptoglobin
No active cancer in previous year The French score considered patients with a thrombotic microangiopathy (TMA) syndrome (which includes hemolysis with schistocytes in the definition) and assumes that there is no history of or clinical evidence for associated cancer, transplantation or disseminated intravascular coagulopathy; so these items are intrinsic to the score. b MCV was not incorporated in the French score.
c Results correspond to those of the derivation cohort and those of a validation by (French score) the bootstrap resampling technique (internal validation) (Coppo et al, 12 Bendapudi et al, 13 and manuscript in preparation), or (PLASMIC score) different samples of patients from the same institution (internal validation) or from a different institution (external validation). 12, 13 ongoing to define more accurately the minimal effective dose of rituximab for this indication (ClinicalTrials.gov, NCT01554514).
The convincing results reported with rituximab in patients with a suboptimal response to standard therapy prompted investigators to evaluate its efficacy as frontline therapy in all patients with iTTP. In 2011, the UK group reported that frontline treatment with rituximab resulted in shorter hospitalization and fewer relapses that occurred later than in a historical group not treated with rituximab. 26 Fewer and later relapses were also seen in rituximab treated patients by the French TMA Reference Center Network 23 and the Oklahoma TTP registry.
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Although the time to response with rituximab is shorter in iTTP (median, 2 weeks between the first infusion and durable platelet count recovery) than for many other autoimmune diseases, 23, 26 rituximab failed to prevent early deaths occurring in the first 10 days, 23 leaving a crucial unmet need.
| THE UNMET NEEDS WITH STANDARD TREATMENT
TPE transformed the historically fatal prognosis of iTTP to a treatable disease with an overall survival rate of 85%. Despite further improvements in the management of iTTP, including immunomodulation with rituximab, the last 20 years have seen only modest gains in survival. 1, 23, 28 The two main causes of death are insufficient awareness of TTP diagnosis, leading to diagnostic delay, 11 and the unmet need for new weapons for the management of the most severe cases, particularly early in the disease course. Another limitation of standard treatment is that TPE and catheter placement represent a cumbersome procedure associated with major complications including infection, bleeding, catheter-associated thrombosis, toxicities of plasma infusion, and death. 29 It is hoped that new drugs stemming from a better understanding of TTP pathophysiology will potentially bring about further reductions in mortality and healthcare burden. Figure 1 and Algorithm A1).
| THE FORTHCOMING THERAPEUTIC ARSENAL

| Caplacizumab: inhibiting von Willebrand factor-platelet interaction
In conclusion, caplacizumab may improve survival of patients with iTTP in the early phase of the disease until improvement of ADAMTS13 activity with B-cell depleting therapies, which usually occurs within 30 days. 23, 26 Consequently, ADAMTS13 activity should be monitored closely (for example, once per week) after platelet count recovery to determine the optimal time for stopping caplacizumab when ADAMTS13 is no longer severely deficient (for example, ADAMTS13 activity >20%). Forthcoming studies that focus specifically on the impact of caplacizumab on outcomes in the most severely affected patients are anxiously awaited.
| RECOMBINANT ADAMTS13: THE NEXT STEP?
The identification of ADAMTS13 as the key missing component in TTP-fueled development of a recombinant form of the protein (rADAMTS13) (SHP655; BAX930), for which tolerability and efficacy were recently evaluated in a phase 1 study of patients with congenital TTP. The therapeutic enzyme was reported to be safe and well tolerated, with a half-life of 53 hours, which is comparable to the halflife of wild-type ADAMTS13. 32 No significant adverse events were reported; specifically, no anti-ADAMTS13 antibodies were detected.
Finally, the study provided evidence of rADAMTS13 activity: platelet counts increased and the larger multimers of VWF decreased. 
| MANAGEMENT OF PATIENTS FOLLOWING THE ACUTE PHASE
| Prevention of relapses
Historically, 40% of patients with iTTP experience one or multiple relapses. 37 Relapses result from severe ADAMTS13 deficiency caused by the persistence or recurrence of anti-ADAMTS13 autoantibodies.
Whereas persistent severe ADAMTS13 deficiency during remission has been consistently associated with clinical relapse, the predictive value of anti-ADAMTS13 antibodies for iTTP relapse remains controversial. 38, 39 Younger age was also associated with an increased risk of relapse in one study. 39 Each relapse exposes the patient to risk of death and to complications related to TPE or to intensive care unit hospitalization. Therefore, the prevention of relapse in TTP represents a major goal. As detailed above, the use of rituximab in the acute phase of the disease dramatically decreases the relapse rate at 1 year.
However, beyond this period, anti-ADAMTS13 autoantibodies may recur along with peripheral B-cell reconstitution, exposing patients to risk of clinical relapse. These observations provided a rationale to evaluate the efficacy of rituximab in iTTP as preemptive therapy for patients in clinical remission, but with persistent or recurrent severe ADAMTS13 deficiency. In this context, rituximab remarkably reduces the incidence of iTTP relapse by diminishing the production of anti-ADAMTS13 antibodies and rapidly restoring ADAMTS13 activity, which parallels peripheral B cell depletion. [40] [41] [42] In our practice, we assess ADAMTS13 regularly during follow-up (typically every 3 months). After serial ADAMTS13 assessments have remained normal (>50%) durably (typically 3 years), measurements are spaced out to twice a year for 2 years and then yearly. When ADAMTS13 activity becomes undetectable (activity <10% or even <20%), a single Consequently, further rituximab infusions may be required to maintain a detectable ADAMTS13 activity and prevent clinical relapse. [40] [41] [42] Patients with persistent severe (activity <10%-20%) ADAMTS13 deficiency are exposed to a high risk of relapse, with a 7-year cumulative incidence of relapse of 74%. 42 Moreover, 10%-15% of patients are primarily unresponsive to rituximab or experience refractoriness after an initial response. 40 In these cases, a more intensive regimen 
| Long-term follow-up: connective tissue diseases, cognitive disturbances, and greater risk of death
iTTP is associated with an increased risk for other autoimmune diseases (mostly systemic lupus erythematosus and Sjögren's syndrome), which may present before, concomitant with, or after diagnosis of iTTP. The cumulative incidence of autoimmune disorders after iTTP diagnosis is 9.9% after 5 years, 13.5% after 10 years, and 25.9% after 12 years.
50,51
The incidence is higher after rather than before the first iTTP episode and increases over time, suggesting a role for increasing age.
Recent data have emphasized that after recovery from acute episodes of iTTP, patients report minor cognitive abnormalities as well as problems with concentration and endurance, possibly resulting from posttraumatic stress disorder. Such complications need to be recognized and appropriately managed. Of note, neither depression nor cognitive impairment was significantly associated with the occurrence of relapses or ADAMTS13 activity <10%-20% during remission. 52 Moreover, prevalence of hypertension and major depression is greater as is mortality among iTTP survivors in remission compared with a reference population. 51 The excess of early death in patients with a history of iTTP remains unexplained and could result from sudden undiagnosed relapses, increased cardiovascular risk related to persistent severe ADAMTS13 deficiency, organ damage following the acute episode, or other causes.
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When the clinical score suggests a low probability for ADAMTS13 activity <10%, it may be appropriate to withhold treatment for TTP; however the diagnosis of TTP cannot be excluded. In these patients it is critical to search for an alternative etiology for the MAHA and thrombocytopenia, especially atypical (or complement-mediated) hemolytic uremic syndrome (HUS) as well as a post-infection HUS when renal involvement is predominant. If ADAMTS13 activity is subsequently reported to be <10%, treatment for TTP is indicated unless a clear alternative etiology for MAHA and thrombocytopenia has been established. Some patients in whom an alternative etiology for MAHA and thrombocytopenia is clearly established (eg, systemic infection or malignancy) may have ADAMTS13 activity <10%.
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The diagnosis of TTP requires clinical judgment as well as measurement of ADAMTS13 activity. Corticosteroids may be prednisone, 1 mg/kg/ day, or for patients who are acutely ill, high doses of corticosteroids may be given initially (eg, intravenous methylprednisolone, 1000 mg/day for 3 days) before beginning oral prednisone. We use the conventional regimen for rituximab: 375 mg/m 2 /week, four doses once or twice weekly. Current studies are evaluating alternative regimens for rituximab, to determine if a lower dose or fewer infusions are equally efficacious. Caplacizumab is listed as initial treatment although it is not yet approved as treatment for TTP in the United States or Europe. Patients may continue to have deficient ADAMTS13 activity when their platelet count recovers to normal. Therefore weekly measurements of ADAMTS13 activity are important to guide the duration of corticosteroid and caplacizumab treatment. Persistent ADAMTS13 activity <20% requires continued treatment until ADAMTS13 improvement, because exacerbations of TTP may occur when plasma exchange is stopped. Weekly measurements should be continued until ADAMTS13 activity recovers to normal (≥50%). When ADAMTS13 activity returns to normal (≥50%) with effective immunosuppression, serial measurements continue at increasingly greater intervals. Because of the risk for relapse many years after the initial episode, indefinite follow-up with annual measurement of ADAMTS13 activity is important.
The long-term complications of iTTP were described and rec- 
| HOW TO IMPROVE TTP MANAGEMENT?
| Make clinicians more aware of TTP diagnosis
The rapid diagnosis and early initiation of treatment are clearly related to a favorable outcome. Diagnosis of iTTP in an emergency setting is challenged by the rarity of the disease and nonspecificity of presenting signs and symptoms, which may lead to a delay in initiation of treatment. 11, 21 Although the diagnosis of iTTP is still delayed in some patients, clinicians are becoming increasingly aware of this condition.
In line with this statement, the frequency of organ failure (especially cerebral involvement) has decreased in the last 10 years. 12, 53 In an attempt to further improve management of patients with iTTP, various measures are being developed in a growing number of countries. These include educational programs for generalists, emergency department physicians, and other specialists aimed at enhancing recognition and improving management of the disease. Importantly, there should also be educational programs for patients about the typical features suggestive of a relapse.
| More rapidly identify the most severely affected patients
The other important cause of death that must be considered is primary refractory disease. Primary refractory disease is characterized by the absence of platelet count improvement under standard treatment by day 4 and organ involvement, often manifesting as an increased cardiac troponin. These patients require earlier intensified treatment. 9, 31, 54, 55 The prompt availability of ADAMTS13 activity or the use of surrogate markers 12, 13, 56 to predict severe enzyme deficiency, coupled with early prognostic markers such as cardiac troponin and ADAMTS13 antigen/anti-ADAMTS13 autoantibody titers, 9,55 could facilitate adjustment of initial treatment
Algorithm A2
Management of patients with acquired, autoimmune TTP during remission. If ADAMTS13 activity decreases to 20%-49%, more frequent measurements of ADAMTS13 activity are required. If ADAMTS13 activity decreases to <20%, rituximab is recommended to allow recovery of ADAMTS13 activity to normal (≥50%). In approximately 80% of patients in whom ADAMTS13 activity decreases to <20% during remission, activity will return to normal with rituximab, often with only a single administration. If only partial recovery occurs (ADAMTS13 activity 20%-50%), then no further rituximab is required, but more frequent measurements of ADAMTS13 activity are recommended. If maintenance rituximab for 2 y does not cause recovery of ADAMTS13 activity to <20%, alternative treatments (eg cyclosporine, splenectomy) may be considered or the patient may be followed without further treatment. • Repeat ADAMTS13 every 3 months x 3 years, every 6 months x 2 years, then annually to the severity of the disease and improve the historical 10%-15% death rate in the acute phase.
| Reference centers with experienced practitioners
TTP and other TMAs represent rare diseases requiring a high level of skill for their management. These disorders require dedicated national or regional reference centers which have been established in an increasing number of countries. 57, 58 In France, the Rare Diseases National Plan provides expertise for management of rare disorders, a platform for conducting studies, and resources and information for patients, their families, and their physicians.
Telemedicine allows reference centers to provide services to remote locations. TTP and the other TMA syndromes may be particularly amenable to telemedicine approaches because of the need to answer reports promptly at all hours of the day. 58 Future work should evaluate the effectiveness of telemedicine activity from reference centers on outcomes in patients with rare diseases including iTTP. foster a common language and study designs that will facilitate meta-analyses and data synthesis in the future. There is no doubt that the understanding of iTTP will require close collaboration between multiples disciplines, including hematology, transfusion medicine, nephrology, internal medicine, immunology, and intensive care medicine.
| Improve the level of evidence of therapeutic studies in TTP
| UNANSWERED QUESTIONS IN TTP MANAGEMENT
As new standards in the management of iTTP are defined 15 and new treatments are implemented, new questions will need to be addressed, ideally through international collaborative studies:
1. Are diagnostic algorithms, (particularly platelet count and serum creatinine level), 4, 13, 14 
| CONCLUSION: TTP AS A SUCCESSFUL EXAMPLE FOR TRANSLATIONAL MEDICINE
The prospect of targeted therapies promises to alter the landscape of TTP therapy in the coming years. In particular, the combination of recombinant ADAMTS13 in association with immunomodulation (steroids and B-cell depletion) and caplacizumab may constitute a therapeutic triplet that reduces the number of TPE sessions, shortens hospital stay, and improves survival. TTP has entered the era of targeted therapies and the history of this disease can be considered as a convincing example of the success of translational medicine.
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